pioglitazone hydrochloride has been researched along with Alloxan Diabetes in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujita, T; Ikeda, H; Meguro, K; Mizuno, K; Momose, Y; Sohda, T | 1 |
| Hamaguchi, W; Maruyama, T; Misawa-Mukai, H; Negoro, K; Ohta, M; Takeuchi, M; Yonetoku, Y; Yoshida, S | 1 |
2 other study(ies) available for pioglitazone hydrochloride and Alloxan Diabetes
| Article | Year |
|---|---|
Studies on antidiabetic agents. 11. Novel thiazolidinedione derivatives as potent hypoglycemic and hypolipidemic agents.
Topics: Animals; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Mice; Pioglitazone; Structure-Activity Relationship; Thiazoles; Thiazolidinediones | 1992 |
Discovery and biological evaluation of novel 4-amino-2-phenylpyrimidine derivatives as potent and orally active GPR119 agonists.
Topics: Administration, Oral; Animals; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Drug Discovery; Glucose Tolerance Test; Haplorhini; HEK293 Cells; Humans; Hypoglycemic Agents; Male; Mice; Mice, Inbred ICR; Molecular Structure; Pyrimidines; Receptors, G-Protein-Coupled; Structure-Activity Relationship | 2012 |